Private company
Who owns GreenLight Biosciences Holdings, PBC
One company in the researched set discloses a stake in GreenLight Biosciences Holdings, PBC, none of it sized by anyone who discloses it. GreenLight Biosciences Holdings, PBC is private, so no 13F reports it: a 13F covers exchange listed positions only. These figures exist because each holder disclosed the stake in its own filings.
GreenLight Biosciences Holdings, PBC - Profile
- Type
- private company
- Based in
- United States
GreenLight Biosciences is a Massachusetts biotechnology company, registered as a public benefit corporation and based in Lexington, that develops products built on RNA. Its cell free manufacturing platform produces double stranded and messenger RNA at agricultural rather than pharmaceutical cost, and the company applies it across human, animal and plant health: messenger RNA vaccines and therapeutics on the human side, and RNA interference sprays that switch off specific genes in pests on the agricultural side. Its first commercial product, the bioinsecticide Calantha, whose active ingredient is ledprona, was registered by the United States Environmental Protection Agency in January 2024 as the first foliar applied RNA pesticide approved under section 3 of FIFRA, and it targets the Colorado potato beetle. The company listed on Nasdaq through a blank cheque merger in 2022 and was taken private in July 2023 by a consortium led by Fall Line Capital.
Source
GreenLight Biosciences Holdings, PBC files nothing with the SEC, so none of this comes from a filer record. The description was written for this site in August 2026 from GreenLight Biosciences 8-K exhibit: completion of merger with Fall Line Endurance Fund, GreenLight Biosciences press release on EPA registration of Calantha and Chemical & Engineering News: EPA allows novel RNAi pesticide. The ownership figures below come from the holders' filings instead, and are sourced row by row.
The disclosed stakes
One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.
Where each figure comes from
A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.
- Alexandria Real Estate Equities, Inc.. ARE's SC 13D filed 8 Jun 2023 (event date 29 May 2023) disclosed Alexandria Venture Investments, LLC (AVI) holding 1,609,909 shares of GreenLight Biosciences Holdings, PBC common stock, 1.06% of the class. That 13D was itself filed as part of a going-private transaction: GreenLight's Rollover Stockholders, including AVI, agreed to contribute their shares to a new private Parent entity in exchange for Series A-2 Preferred Stock of Parent, with Rollover Shares constituting approximately 79.46% of GreenLight's total outstanding shares. No subsequent ARE filing discloses whether this merger closed, the size of AVI's resulting preferred stake in the now-private Parent, or whether the position is still held. Per the project's rule against inventing a number, no share count, percentage, or value is modelled for the current (post-merger) private stake; the pre-merger 1,609,909-share, 1.06% figure is stale and superseded by the rollover, so it is not carried into shares/pct_of_target either. source
What this page is not
It is not a complete register. It lists the holders who happen to be inside the researched set and disclosed the stake themselves. A private company can have many other shareholders, and nothing here rules them out: venture investors, founders and employees usually appear in no public filing at all. Percentages are of GreenLight Biosciences Holdings, PBC where a holder stated one, and are missing where no holder did.